Hepatitis B virus (HBV) Infections and Infestations Acute hepatitis B
Conditions
Interventions
The intervention provided in this trial will be the administration of the Engerix-B adult formulation HBV vaccine adhering to one of two vaccine schedules. Participants will receive an initial vaccine
Sponsors
The Burnet Institute (Australia)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Participants who are at risk of contracting HBV (or those not already immune or infected), will be identified from existing Burnet Institute cohort studies and approached to participate.
Exclusion criteria
Exclusion criteria: Participants from Burnet Institute Cohort studies who are vaccinated or immune to HBV.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Increasing vaccine coverage amongst this cohort of people 2. Measuring vaccine course completion between the standard schedule and the the opportunistic accelerated schedule 3. Measuring immunological vaccine response between the standard schedule and the the opportunistic accelerated schedule | — |
Secondary
| Measure | Time frame |
|---|---|
| Assessing the acceptability and feasibility of an assertive outreach model of vaccine delivery | — |
Countries
Australia
Outcome results
None listed